Synthesis and evaluation of 2‐aryl‐1H‐benzo[d]imidazole derivatives as potential microtubule targeting agents
Sign Up to like & getrecommendations! Published in 2022 at "Drug Development Research"
DOI: 10.1002/ddr.21909
Abstract: Microtubule targeting agents (MTAs) are the potential drug candidates for anticancer drug discovery. Disrupting the microtubule formation or inhibiting the de‐polymerization process by a synthetic molecule can lead to an excellent anticancer drug candidate. Here,… read more here.
Keywords: microtubule targeting; benzo imidazole; imidazole derivatives; microtubule ... See more keywords
Treatment dynamics of bone‐targeting agents among men with bone metastases from prostate cancer in the United States
Sign Up to like & getrecommendations! Published in 2018 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.4360
Abstract: To examine the dynamics of treatment with 2 bone‐targeting agents (BTAs)—denosumab and zoledronic acid—among men with bone metastases from prostate cancer. read more here.
Keywords: bone targeting; bone metastases; metastases prostate; targeting agents ... See more keywords
Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03815-z
Abstract: CD47, a transmembrane protein, acts as a “do not eat me” signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRPα) and enabling… read more here.
Keywords: cd47 targeting; cd47; blockade; targeting agents ... See more keywords
Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2022.114274
Abstract: Autophagy is a lysosome dependent cell survival mechanism and is central to the maintenance of organismal homeostasis in both physiological and pathological situations. Targeting autophagy in cancer therapy attracted considerable attention in the past as… read more here.
Keywords: cancer; microtubule targeting; targeting agents; cell ... See more keywords
Dynamic Covalent Template-Guided Screen for Nucleic Acid-Targeting Agents.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01086
Abstract: Trinucleotide repeat diseases such as myotonic dystrophy type 1 (DM1) and Huntington's disease (HD) are caused by expanded DNA repeats that can be used as templates to synthesize their own inhibitors. Because it would be… read more here.
Keywords: nucleic acid; dynamic covalent; chemistry; acid targeting ... See more keywords
The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 4: miscellaneous cancers.
Sign Up to like & getrecommendations! Published in 2022 at "British dental journal"
DOI: 10.1038/s41415-022-3983-6
Abstract: This article discusses relevant information for the dental sector regarding metastatic cancers beyond breast and prostate cancer. Typically, tumour sites such as lung, renal, colorectal, gastrointestinal, thyroid, hepatic and pancreatic cancers are increasingly being referred… read more here.
Keywords: bone; bone metastases; presenting dental; bone targeting ... See more keywords
Methyl-β-cyclodextrin, an actin depolymerizer augments the antiproliferative potential of microtubule-targeting agents
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-43947-4
Abstract: Methyl-β-cyclodextrin (MCD), an established pharmacological excipient, depolymerizes the actin cytoskeleton. In this work, we investigated the effect of MCD-mediated actin depolymerization on various cellular phenotypes including traction force, cell stiffness, focal adhesions, and intracellular drug… read more here.
Keywords: actin; methyl cyclodextrin; targeting agents; cancer ... See more keywords
Abstract 5037: DARPins as powerful targeting agents for radioligand therapeutics
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5037
Abstract: The development of effective radioligand therapeutics (RLTs) is frequently hampered by the lack of high-quality targeting agents that selectively deliver radioactive payloads to the site of disease while sparing healthy tissues. Antibodies can have high… read more here.
Keywords: radioligand therapeutics; affinity; targeting agents; darpin ... See more keywords
Abstract 935: Co-clinical endometrial cancer (EC) patient-derived organoids (PDO) to assess functional effects of replication stress (RS)-targeting agents
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-935
Abstract: Background: EC is the most commonly diagnosed gynecologic cancer in the US and has both rising incidence and mortality. Uterine serous cancer (USC) and uterine carcinosarcoma (UCS) are high grade ECs characterized by TP53 mutation… read more here.
Keywords: replication; cancer; replication stress; targeting agents ... See more keywords
Abstract 6759: In vivo tumor growth control by general control nonderepressible 2 targeting agents results from kinase activation
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6759
Abstract: General Control Nonderepressible 2 (GCN2; EIF2AK4) is a serine-threonine kinase in the integrated stress response (ISR) signaling pathway that initiates adaptive responses during nutrient stress conditions. While pharmacological inhibition of GCN2 under nutrient stress conditions… read more here.
Keywords: control; tumor growth; targeting agents; gcn2 ... See more keywords
Effects of nivolumab alone or combination with molecular targeting agents for recurrent and refractory endometrial cancers with biomarker analyses.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e17124
Abstract: e17124 Background: The immunotherapy drug, nivolumab, is now approved for several metastatic cancers, and has resulted in responses previously not seen with these cancers. Molecular targeting agents, such as mammalian target of rapamycin (mTOR) inhibitor,… read more here.
Keywords: histology; targeting agents; molecular targeting; alone combination ... See more keywords